Gα13-mediated transformation and apoptosis are permissively dependent on basal ERK activity

American Journal of Physiology - Cell Physiology

Volumn 285, Issue 4 54-4, 2003, Pages

  Adarichev, Vyacheslav A ^a   Vaiskunaite, Rita ^a   Niu, Jiaxin ^a   Balyasnikova, Irina V ^a   Voyno Yasenetskaya, Tatyana A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Effector mutant; Mitogen activated kinase; Src kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GENISTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; POLYPEPTIDE; PROTEIN G13; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOP CODON;

ANIMALIA;

EID: 0141679497     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00115.2003     Document Type: Article

References (59)

1. 13 trigger apoptosis through different pathways. J Biol Chem 272: 24380-24386, 1997.
2. Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B, and Joubert D. Invasive human pituitary tumors express a point-mutated alpha-protein kinase C. J Clin Endocrinol Metab 77: 1125-1129, 1993.
3. Aspenstrom P. Effectors for the Rho GTPases. Curr Opin Cell Biol 11: 95-102, 1999.
4. 13 proteins via apoptosis signal-regulated kinase, Ask1. J Biol Chem 273: 27816-27823, 1998.
5. s. Cell 68: 911-922, 1992.
6. Bourne HR, Sanders DA, and McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349: 117-127, 1991.
7. Buckley S, Driscoll B, Barsky L, Weinberg K, Anderson K, and Warburton D. ERK activation protects against DNA damage and apoptosis in heperoxic rats. Am J Physiol Lung Cell Mol Physiol 277: L159-L166, 1999.
8. 12 gene product. Mol Cell Biol 13: 762-768, 1993.
9. Chang CL, Zhu XX, Thoraval DH, Ungar D, Rawwas J, Hora N, Strahler JR, Hanash SM, and Radany E. Nm23-H1 mutation in neuroblastoma. Nature 370: 335-336, 1994.
10. Chen Y, Lu Q, Schneeberger EE, and Goodenough DA. Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Mol Biol Cell 11: 849-862, 2000.
11. i1. GppNHp, autoinhibition in a Gα protein-substrate complex. J Biol Chem 274: 16669-16672, 1999.
12. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS, and Spiegel S. Suppression of ceramide-mediated cell death by sphingosine-1-phosphate. Nature 381: 800-803, 1996.
13. 12 activates proliferation and inhibits differentiation of 3T3-F442A preadipocytes. Endocrinology 139: 2892-2899, 1998.
14. s, or thyrotropin-releasing hormone receptor genes. J Clin Endocrinol Metab 81: 1134-1140, 1996.
15. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, and Trujillo JM. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res 36: 467-475, 1976.
16. Drewinko B, Yang LY, Barlogie B, Romsdahl M, Meistrich M, Malahy MA, and Giovanella B. Further biologic characteristics of a human carcinoembryonic antigen-producing colon carcinoma cell line. J Natl Cancer Inst 61: 75-83, 1978.
17. Erhardt P, Schremser EJ, and Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating MEK/ ERK pathway. Mol Cell Biol 19: 308-315, 1999.
18. Farfel Z, Bourne HR, and Iiri T. Mechanisms of disease: the expanding spectrum of G protein disease. N Engl J Med 340: 1012-1020, 1999.
19. Faure M, Voyno-Yasenetskaya TA, and Bourne HR. cAMP and βγ subunits of heterotrimeric G proteins stimulate the mitogen-activated protein kinase pathway in COS-7 cells. J Biol Chem 269: 7851-7854, 1994.
20. Jacinto E, Werlen G, and Karin M. Cooperation between Syk and Rac1 leads to synergistic JNK activation in T lymphocytes. Immunity 8: 31-41, 1998.
21. 12. FEBS Lett 330: 319-322, 1993.
22. Kabouridis PS, Waters ST, Escobar S, Stanners J, and Tsoukas CD. Expression of GTP-binding protein alpha subunits in human thymocytes. Mol Cell Biochem 144: 45-51, 1995.
23. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelest L, Wigler MH, and Der CJ. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 16: 3923-3933, 1996.
24. Lambright DG, Noel JP, Hamm HE, and Sigler PB. The 1.8. A crystal structure of transducin α. GDP: structural determinants for activation of a heterotirmeric G protein α subunit. Nature 369: 621-628, 1994.
25. s protein. J Clin Endocrinol Metab 71: 1416-1420, 1990.
26. s and stimulate adenylyl cyclase in human pituitary tumours. Nature 340: 692-696, 1989.
27. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, and Landvatter SW. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746, 1994.
28. Lem J, Chin AC, Thayer MJ, Leach RJ, and Fournier RE. Coordinate regulation of two genes encoding gluconeogenic enzymes by the trans-dominant locus Tse-1. Proc Natl Acad Sci USA 85: 7302-7306, 1988.
29. Lewis TS, Shapiro PS, and Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139, 1998.
30. Li Y, Sternweis PM, Charnecki S, Smith TF, Gilman AG, Neer EJ, and Kozasa T. Sites for Gα binding on the G protein β subunit overlap with sites for regulation of phospholipase C β and adenylyl cyclase. J Biol Chem 273: 16265-16272, 1998.
31. Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Qian C, Christensen E, Roches PC, Smith DI, and Thibodeau SN. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 26: 146-147, 2000.
32. Lyons J, Landis CA, Harsh G, Vallar L, Grünewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR, and McCormick F. Two G protein oncogenes in human endocrine tumors. Science 249: 655-659, 1990.
33. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, and Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994.
34. 13 with the cytoplasmic domain of cadherin provides a mechanism for beta-catenin release. Proc Natl Acad Sci USA 98: 519-524, 2001.
35. 1 to S phase cell cycle progression on both Ras/mitogen-activated protein kinase and Ras/Rac1/Jun N-terminal kinase cascades in NIH3T3 fibroblasts. J Biol Chem 272: 4904-4910, 1997.
36. 12. Oncogene 18: 4425-4434, 1999.
37. 13 protein that mediates cAMP-independent PKA activation. Curr Biol 11: 1-5, 2001.
38. a.Orita M, Iwahana H, Kanazawa H, Hayashi K, and Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770, 1989.
39. 12 induces neoplastic transformation of Rat-1 cells. Proc Natl Acad Sci USA 88: 7031-7035, 1991.
40. Peitsch MC. ProMod and Swiss-model: internet-based tools for automated comparative protein modelling. Biochem Soc Trans 24: 274-279, 1996.
41. Rodrigues GA, Park M, and Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 16: 2634-2645, 1997.
42. Shievella AR, Chen JH, Graham JR, and Lin LL. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. J Biol Chem 272: 12069-12075, 1997.
43. Sieder S, Richter E, Becker K, Heins R, and Steinfelder HJ. Doxorubicin-resistant LoVo adenocarcinoma cells display resistance to apoptosis induction by some but not all inhibitors of ser/thr phosphatases 1 and 2A. Toxicology 134: 109-115, 1999.
44. Su B and Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402-411, 1996.
45. Sunahara RK, Tesmer JJ, Gilman AG, and Sprang SR. Crystal structure of the adenylyl cyclase activator Gsα. Science 278: 1943-1947, 1997.
46. iα1: stabilization of the transition state for GTP hydrolysis. Cell 89: 251-261, 1997.
47. Treisman R. Ternary complex factors: growth factor regulated transcriptional activators. Curr Opin Genet Dev 4: 96-101, 1994.
48. 13 protein a subunit. J Biol Chem 275: 26206-26212, 2000.
49. 12 signaling. J Biol Chem 267: 46088-46093, 2001.
50. 13. J Biol Chem 270: 18655-18659, 1995.
51. Vleminckx K, Vakaet L, Mareel M, Fiers W, and van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107-119, 1991.
52. Voyno-Yasenetskaya TA, Faure M, Ahn N, and Bourne HR. Gα12 and Gα13 regulate ERK and JNK pathways by different mechanisms in COS-7 cells. J Biol Chem 271: 21081-21087, 1996.
53. 13 proteins induce neoplastic transformation of Rat-1 fibroblasts. Oncogene 9: 2559-2565, 1994.
54. Wang X, Martindale JL, Liu Y, and Holbrook NJ. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signaling pathways on cell survival. Biochem J 333: 291-300, 1998.
55. Widmann C, Gibson S, and Jarpe MD. Mitogen-activated protein kinases: conservation of a three kinase module from yeast to human. Physiol Rev 79: 143-180, 1999.
56. Wittinghofer A. Signal transduction via Ras. Biol Chem 379: 933-937, 1998.
57. Xia Z, Dickens M, Raingeaud J, Davis RJ, and Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
58. 12 potentiates the eicosanoid pathway and is highly oncogenic in NIH3T3 cells. Proc Natl Acad Sci USA 90: 6741-6745, 1993.
59. 13 subunit defines a novel family of oncogenes. Biochem Biophys Res Commun 201: 603-609, 1994.